Nieuwe ontwikkelingen in de behandeling van het pancreascarcinoom

Translated title of the contribution: New developments in the treatment of pancreatic cancer

Hendrik A. Marsman*, Marc G. Besselink, Casper H. Van Eijck, Jeanin E. Van Hooft, Geertjan Van Tienhoven, Krijn P. Van Lienden, Hanneke W. Wilmink, Olivier R. Busch

*Corresponding author for this work

Research output: Contribution to journalArticleAcademic


The incidence of pancreatic cancer is increasing due to the ageing population among other things, while 5year survival has improved in the past two decades from 3 to 7%. In case of biliary obstruction due to pancreatic cancer, biliary drainage before surgery or ablative therapy using a covered metal stent instead of plastic reduces the rate of complications. In patients with metastasized pancreatic cancer a combination of folinic acid, fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX) results in improved survival. Approximately 20% of patients with locally, unresectable pancreatic cancer can undergo surgical resection following treatment with FOLFIRINOX. The effectiveness of radiofrequency ablation, irreversible electroporation and stereotactic radiotherapy for locally, unresectable pancreatic cancer is currently investigated in multicenter trials. The effectiveness of neoadjuvant chemoradiation and minimal invasive surgery in patients with resectable pancreatic cancer is currently investigated in randomized multicenter trials.

Translated title of the contributionNew developments in the treatment of pancreatic cancer
Original languageDutch
Article numberD538
JournalNederlands Tijdschrift voor Geneeskunde
Issue number42
Publication statusPublished - 2016


Dive into the research topics of 'New developments in the treatment of pancreatic cancer'. Together they form a unique fingerprint.

Cite this